Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled phase 2 study of ITF2357 for mucosal healing in moderate-to-severe Crohn's disease
2007-000189-19Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ITF2357 with Placebo (2 arms). Primary endpoint: Complete mucosal healing at week 8. Started Jun 2007; status: terminated.
02
Drugs
givinostat
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2007-000189-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000189-19.